MCL-1 dependency of cisplatin-resistant cancer cells

Biochemical Pharmacology

Volumn 92, Issue 1, 2014, Pages 55-61

  Michels, Judith ^a,b,c   Obrist, Florine ^a,b,c,d   Vitale, Ilio ^e   Lissa, Delphine ^a,b,c   Garcia, Pauline ^a,b,c   Behnam Motlagh, Parviz ^f   Kohno, Kimitoshi ^g   Wu, Gen Sheng ^h   Brenner, Catherine ^d   Castedo, Maria ^a,b,c   Kroemer, Guido ^a,b,c,i  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Metabolomics and Cell Biology Platforms Gustave Roussy Cancer Campus   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f UMEÅ UNIVERSITY   (Sweden)

^g UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^h WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Apoptosis; Chemoresistance; MCL 1; Obatoclax; PARP1

Indexed keywords

BH3 PROTEIN; CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN MCL 1; ANTINEOPLASTIC AGENT; MCL1 PROTEIN, HUMAN; MYELOID LEUKEMIA FACTOR 1; OBATOCLAX; PARP1 PROTEIN, HUMAN; PYRROLE DERIVATIVE;

ARTICLE; CANCER CELL; CANCER CELL LINE; HUMAN; METABOLISM; MONOTHERAPY; NEOPLASM; NON SMALL CELL LUNG CANCER; PROTEIN DEPLETION; RNA INTERFERENCE; UPREGULATION; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; POLY(ADP-RIBOSE) POLYMERASES; PYRROLES; RNA INTERFERENCE;

EID: 84908303131     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.07.029     Document Type: Article

References (46)

1. A.W. Prestayko, J.C. D'Aoust, B.F. Issell, and S.T. Crooke Cisplatin (cis-diamminedichloroplatinum II) Cancer Treat Rev 6 1 1979 17 39
2. D. Lebwohl, and R. Canetta Clinical development of platinum complexes in cancer therapy: an historical perspective and an update Eur J Cancer 34 10 1998 1522 1534
3. M. Galanski Recent developments in the field of anticancer platinum complexes Recent Pat Anticancer Drug Discov 1 2 2006 285 295
4. R.F. Ozols Ovarian cancer: new clinical approaches Cancer Treat Rev 18 Suppl. A 1991 77 83
5. G. Giaccone Clinical perspectives on platinum resistance Drugs 59 Suppl. 4 2000 9 17 discussion 37-18
6. B. Koberle, M.T. Tomicic, S. Usanova, and B. Kaina Cisplatin resistance: preclinical findings and clinical implications Biochim Biophys Acta 1806 2 2010 172 182
7. L. Galluzzi, L. Senovilla, I. Vitale, J. Michels, I. Martins, and O. Kepp Molecular mechanisms of cisplatin resistance Oncogene 31 15 2012 1869 1883
8. L. Galluzzi, I. Vitale, J. Michels, C. Brenner, G. Szabadkai, and A. Harel-Bellan Systems biology of cisplatin resistance: past, present and future Cell Death Dis 5 2014 e1257
9. S.M. Cohen, and S.J. Lippard Cisplatin: from DNA damage to cancer chemotherapy Prog Nucleic Acid Res Mol Biol 67 2001 93 130
10. G. Kroemer, L. Galluzzi, and C. Brenner Mitochondrial membrane permeabilization in cell death Physiol Rev 87 1 2007 99 163
11. S. Fulda, L. Galluzzi, and G. Kroemer Targeting mitochondria for cancer therapy Nat Rev Drug Discov 9 6 2010 447 464
12. M. Castedo, A. Coquelle, S. Vivet, I. Vitale, A. Kauffmann, and P. Dessen Apoptosis regulation in tetraploid cancer cells EMBO J 25 11 2006 2584 2595
13. B.M. Erovic, M. Pelzmann, M. Grasl, J. Pammer, G. Kornek, and W. Brannath Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck Clin Cancer Res 11 24 Pt 1 2005 8632 8636
14. J.Y. Han, E.K. Hong, B.G. Choi, J.N. Park, K.W. Kim, and J.H. Kang Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer Med Oncol 20 4 2003 355 362
15. H.V. Jain, and M. Meyer-Hermann The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas Cancer Res 71 3 2011 705 715
16. W.A. Michaud, A.C. Nichols, E.A. Mroz, W.C. Faquin, J.R. Clark, and S. Begum Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma Clin Cancer Res 15 5 2009 1645 1654
17. N. Tajeddine, L. Galluzzi, O. Kepp, E. Hangen, E. Morselli, and L. Senovilla Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death Oncogene 27 30 2008 4221 4232
18. J. Williams, P.C. Lucas, K.A. Griffith, M. Choi, S. Fogoros, and Y.Y. Hu Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease Gynecol Oncol 96 2 2005 287 295
19. L. Galluzzi, I. Vitale, L. Senovilla, K. Olaussen, G. Pinna, and T. Eisenberg Prognostic impact of vitamin B6 metabolism in lung cancer Cell Rep 2 2 2012 257 269
20. J. Michels, I. Vitale, L. Senovilla, K.A. Olaussen, G. Pinna, and T. Eisenberg Cisplatin resistance associated with PARP hyperactivation Cancer Res 73 7 2013 2271 2280
21. V. Janson, A. Johansson, and K. Grankvist Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance Cell Death Dis 1 2010 e78
22. G. Hirano, H. Izumi, A. Kidani, Y. Yasuniwa, B. Han, and H. Kusaba Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells Mol Cancer Res 8 6 2010 864 872
23. J. Wang, J.Y. Zhou, L. Zhang, and G.S. Wu Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells Cell Cycle 8 19 2009 3191 3198
24. A. Criollo, M.C. Maiuri, E. Tasdemir, I. Vitale, A.A. Fiebig, and D. Andrews Regulation of autophagy by the inositol trisphosphate receptor Cell Death Differ 14 5 2007 1029 1039
25. J. Hoffmann, I. Vitale, B. Buchmann, L. Galluzzi, W. Schwede, and L. Senovilla Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone Cancer Res 68 13 2008 5301 5308
26. O. Kepp, L. Galluzzi, M. Lipinski, J. Yuan, and G. Kroemer Cell death assays for drug discovery Nat Rev Drug Discov 10 3 2011 221 237
27. L. Galluzzi, S.A. Aaronson, J. Abrams, E.S. Alnemri, D.W. Andrews, and E.H. Baehrecke Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes Cell Death Differ 16 8 2009 1093 1107
28. S. Trudel, Z.H. Li, J. Rauw, R.E. Tiedemann, X.Y. Wen, and A.K. Stewart Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma Blood 109 12 2007 5430 5438
29. S. Cory, D.C. Huang, and J.M. Adams The Bcl-2 family: roles in cell survival and oncogenesis Oncogene 22 53 2003 8590 8607
30. G. Lessene, P.E. Czabotar, and P.M. Colman BCL-2 family antagonists for cancer therapy Nat Rev Drug Discov 7 12 2008 989 1000
31. M. Vogler, D. Dinsdale, M.J. Dyer, and G.M. Cohen Bcl-2 inhibitors: small molecules with a big impact on cancer therapy Cell Death Differ 16 3 2009 360 367
32. M. Nguyen, R.C. Marcellus, A. Roulston, M. Watson, L. Serfass, and S.R. Murthy Madiraju Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis Proc Natl Acad Sci U S A 104 49 2007 19512 19517
33. P.N. Kelly, and A. Strasser The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy Cell Death Differ 18 9 2011 1414 1424
34. K.J. Campbell, M.L. Bath, M.L. Turner, C.J. Vandenberg, P. Bouillet, and D. Metcalf Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance Blood 116 17 2010 3197 3207
35. T.G. Whitsett, I.T. Mathews, M.H. Cardone, R.J. Lena, W.E. Pierceall, and M. Bittner Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response Mol Cancer Res 12 4 2014 550 559
36. P. Zhou, N.B. Levy, H. Xie, L. Qian, C.Y. Lee, and R.D. Gascoyne MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes Blood 97 12 2001 3902 3909
37. R. Beroukhim, C.H. Mermel, D. Porter, G. Wei, S. Raychaudhuri, and J. Donovan The landscape of somatic copy-number alteration across human cancers Nature 463 7283 2010 899 905
38. M.M. Borner, P. Brousset, B. Pfanner-Meyer, M. Bacchi, S. Vonlanthen, and M.A. Hotz Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer Br J Cancer 79 5-6 1999 952 958
39. L. Luo, T. Zhang, H. Liu, T. Lv, D. Yuan, and Y. Yao MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance Med Oncol 29 3 2012 1681 1686
40. T. Zhang, C. Zhao, L. Luo, H. Zhao, J. Cheng, and F. Xu The expression of Mcl-1 in human cervical cancer and its clinical significance Med Oncol 29 3 2012 1985 1991
41. G. Vinothini, R.S. Murugan, and S. Nagini Mitochondria-mediated apoptosis in patients with adenocarcinoma of the breast: correlation with histological grade and menopausal status Breast 20 1 2011 86 92
42. T.D. Allen, C.Q. Zhu, K.D. Jones, N. Yanagawa, M.S. Tsao, and J.M. Bishop Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer Cancer Res 71 6 2011 2212 2221
43. Q. Ding, X. He, J.M. Hsu, W. Xia, C.T. Chen, and L.Y. Li Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization Mol Cell Biol 27 11 2007 4006 4017
44. D. Nijhawan, M. Fang, E. Traer, Q. Zhong, W. Gao, and F. Du Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation Genes Dev 17 12 2003 1475 1486
45. Q. Zhong, W. Gao, F. Du, and X. Wang Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis Cell 121 7 2005 1085 1095
46. J. Luo, N.L. Solimini, and S.J. Elledge Principles of cancer therapy: oncogene and non-oncogene addiction Cell 136 5 2009 823 837